Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in patients with Crohn’s disease – The Pharmacogenomics Journal

Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60: 571-607. https://doi.org/10.1136/gut.2010.224154

Article PubMed Google Scholar

Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Jam J Gastroenterol. 2012; 107:23–34. https://doi.org/10.1038/ajg.2011.401

Google Scholar Article

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Jam J Gastroenterol. 2009; 104: 2089–96. https://doi.org/10.1038/ajg.2009.301

Article CAS PubMed Google Scholar

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362: 1383–95. https://doi.org/10.1056/NEJMoa0904492

Article CAS PubMed Google Scholar

Chaparro M, Panés J, García V, Mendoza JL, Bermejo F, López San Román A, et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term study of 3931 patients. Intestinal inflammation Dis. 2013; 19:1404–10. https://doi.org/10.1097/MIB.0b013e318281f28f

Article PubMed Google Scholar

Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: influence of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002; 12:429-36. https://doi.org/10.1097/00008571-200208000-00003

Article CAS PubMed Google Scholar

Chande N, Laidlaw M, McDonald JW, Macdonald JK. Azathioprine or 6-mercaptopurine for inducing remission in Crohn’s disease. Cochrane Database Syst Rev. 2013; 10:CD000545 https://doi.org/10.1002/14651858.CD000545.pub5

Google Scholar Article

Friedman AB, Sparrow MP, Gibson PR. Role of thiopurine metabolites in inflammatory bowel disease and rheumatologic disorders. Int J Rheum Dis. 2014; 17:132–41. https://doi.org/10.1111/1756-185X.12204

Article CAS PubMed Google Scholar

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Intolerance and heterozygosity of mercaptopurine therapy at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999; 91: 2001–8.

Article CAS PubMed Google Scholar

Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012; 35:15–36. https://doi.org/10.1111/j.1365-2036.2011.04905.x

Article CAS PubMed Google Scholar

Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when receiving thiopurine medications? Pharmacogenomics. 2010; 11:177–88. https://doi.org/10.2217/pgs.09.155

Article CAS PubMed Google Scholar

Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18:395-400. https://doi.org/10.1046/j.1365-2036.2003.01690.x

Article CAS PubMed Google Scholar

Colombel JF, Ferrari N, Debuysère H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118: 1025-30. https://doi.org/10.1016/S0016-5085(00)70354-4

Article CAS PubMed Google Scholar

Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16: 1743-50. https://doi.org/10.1046/j.1365-2036.2002.01353.x

Article CAS PubMed Google Scholar

Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre EM, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Lost Genes. 2002; 111: 360-7. https://doi.org/10.1007/s00439-002-0798-z

Article CAS PubMed Google Scholar

Marinaki AM, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-Bakre M, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004; 14:181–7. https://doi.org/10.1097/00008571-200403000-00006

Article CAS PubMed Google Scholar

Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016; 48: 367–73. https://doi.org/10.1038/ng.3508

Article CAS PubMed PubMed Central Google Scholar

Yang JJ, Whirl-Carrillo M, Scott SA, Turner AJ, Schwab M, Tanaka Y, et al. Gene insertion of the pharmacogenic variation consortium: NUDT15. Clin Pharmacol Ther. 2019; 105: 1091–4. https://doi.org/10.1002/cpt.1411

Article PubMed Google Scholar

Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guidelines for diagnostic evaluation in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019; 13:144–64. https://doi.org/10.1093/ecco-jcc/jjy113

Article PubMed Google Scholar

Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working group of the World Congress of Gastroenterology in Montreal 2005. Can J Gastroenterol. 2005; 19:5–36.

Google Scholar Article

Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet. 1980; 1:514.

Article CAS PubMed Google Scholar

Campbell S, Kingstone K, Ghosh S. Significance of thiopurine methyltransferase activity in patients with inflammatory bowel disease maintained on low-dose azathioprine. Aliment Pharmacol Ther. 2002; 16:389–98. https://doi.org/10.1046/j.1365-2036.2002.01177.x

Article CAS PubMed Google Scholar

Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Association of inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes with azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006; 4:44–49. https://doi.org/10.1016/j.cgh.2005.10.019

Article CAS PubMed Google Scholar

Dewit O, Moreels T, Baert F, Peeters H, Reenaers C, de Vos M, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in patients with IBD. Clin Biochem. 2011; 44: 1062–6. https://doi.org/10.1016/j.clinbiochem.2011.06.079

Article CAS PubMed Google Scholar

Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28:973–83. https://doi.org/10.1111/j.1365-2036.2008.03788.x

Article CAS PubMed Google Scholar

Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, et al. Pharmacogenetics during standardized initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55: 1423-31. https://doi.org/10.1136/gut.2005.074930

Article CAS PubMed PubMed Central Google Scholar

Van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ. ITPA genotype is not predictive for the development of adverse effects in patients with inflammatory bowel disease treated with AZA. Gut. 2005; 54: 1664.

PubMed PubMed Central Google Scholar

Gutiérrez-Valencia M, Leache L, Saiz LC, Beloqui JJ, Barajas M, Vicuña M, et al. The role of pharmacogenomics in thiopurine efficacy and safety in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2023; 57: 671-85.

Article PubMed Google Scholar

Von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, et al. Association of inosine triphosphatase 94C>A deficiency and thiopurine S-methyltransferase deficiency with adverse events and dropouts under azathioprine therapy in a prospective study of Crohn’s disease. Clin Chem. 2005; 51: 2282-8. https://doi.org/10.1373/clinchem.2005.057158

Article CAS Google Scholar

Mañosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly-onset inflammatory bowel disease: a multicenter, case-control study. Aliment Pharmacol Ther. 2018; 47:605–14. https://doi.org/10.1111/apt.14494

Article CAS PubMed Google Scholar